Topic

Teva

Teva is one of Israel’s largest pharmaceutical companies, with operations in generics and branded medicines in markets around the world. TV10 Global’s coverage of Teva tracks earnings reports, share performance, executive transactions, and broader developments in the company’s business, financing, and market outlook.

11 stories on TV10 Global

The Tel Aviv Stock Exchange
Earnings Season Continues

TASE Trading Week: Dual-Listed Stocks Signal Lower Open

Tower is expected to plunge more than 7%, while Nova and Camtek are each expected to lose more than 3% • In contrast, Teva and NICE may stand out positively • Earnings season continues: Leumi, Discount and Elbit Systems will report results this week

TV10 Desk
Teva Pharmaceutical Industries
Breaking

Teva Executives Sold Shares Worth About $3 Million

The interim chief legal officer and a senior vice president for international markets sold more than 72,000 shares of the pharmaceutical company, worth a combined total of about $3.02 million • The sales were reported to the U.S. Securities and Exchange Commission (SEC)

TV10 Desk
The Tel Aviv Stock Exchange
Volatile Trading

TASE Closes Mixed: Which Stock Surged About 34%?

TA-90 fell 0.96%, while TA-35 added about 0.29% • Aura Smart stock plunged about 30% • The euro rose about 0.45% to NIS 3.52, while the dollar traded at NIS 3.16

Shai Nogai
Teva stock
Above expectations

Teva Reports Revenue of $4.4 Billion

Adjusted gross profit margin soared to a decade high of 58.7% • The company raised its annual revenue forecast following sharp growth in innovative medicines

Shai Nogai
The Tel Aviv Stock Exchange
Breaking

TASE Continues to Fall; Sofwave Stock Jumps 9%

Tel Aviv indices open lower for a third consecutive trading day amid earnings season • Sofwave stands out following its third-quarter results, Amot reports moderate NOI growth, and Teva is set to publish its results later today

TV10 Desk
The Tel Aviv Stock Exchange
Breaking

Volatile TASE trading: Perion surges about 30%, Gene Technology rises 7%

Leading indexes trade steadily with a slight upward bias • Perion surges following an agreement to sell it to India’s Affle for about $420 million, while Gene Technology climbs about 7% • Gab-Yam opens the local earnings season with a 68% jump in net profit • Tower, Teva and Camtek are among the companies reporting this week

TV10 Desk
The Tel Aviv Stock Exchange
Breaking

Tel Aviv Earnings Season: Teva, El Al and Tower in Focus This Week

After a month of declines in the Tel Aviv and New York markets, the coming trading week will mark the start of earnings season in Israel and a series of reports from Wall Street giants, including Apple, AMD and Palantir • In the background: concerns over the scale of artificial intelligence investment and the possibility of continued market volatility

TV10 Desk
Teva stock
Hit a Record High

FDA Approves New Teva Schizophrenia Treatment — Stock Jumps

Teva received approval from the U.S. Food and Drug Administration to market WELTRUZA, intended for adults • The new treatment is based on the active ingredient olanzapine and is administered as a once-monthly subcutaneous injection without the need for loading doses • The drug is expected to be available in the United States in the coming weeks

TV10 Editorial Staff
Palo Alto Networks
Unprecedented

History on TASE: Palo Alto Crosses NIS 1 Trillion Valuation

The cybersecurity company’s stock surged 5.48% on Thursday and reached an all-time high on the local exchange • Its new valuation puts it far ahead of the next company on the list, Teva, which trades at a valuation of about NIS 143 billion • The trading day itself ended mixed, with turnover of about NIS 3.2 billion

TV10 Editorial Staff
Teva stock
Upgrade

Turnaround Complete: Teva Regains Investment-Grade Rating From All Agencies

S&P upgraded Teva’s long-term credit rating from BB+ to BBB- with a stable outlook • The move completes the company’s return to investment grade at all three major rating agencies after several years • The company says the upgrade reflects growth in innovative medicines and stabilization in generics

TV10 Editorial Staff